Apolipoprotein E (ApoE) Antibody
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dys beta lipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
| Supplier | Abbexa Ltd. |
|---|---|
| Product # | abx010563-100UL |
| Pricing | 100 µl USD $420.5 |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Host | Mouse |
| Tested Applications | ELISA, IHC, FCM |
| UniProt Primary AC | P02649 |
| Dry Ice | No |
| Availability | Shipped within 5-10 working days. |
| Note | This product is for research use only. |